Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
A poor antibody response of IgM and IgA antibodies upon vaccination with pneumococcal polysaccharides (PnPS) is discussed as independent risk factors for bronchiectasis in patients with antibody deficiency syndrome (ADS) receiving immunoglobulin replacement therapy. However, the kinetics of the specific IgM and IgA response to vaccination with multivalent pneumococcal polysaccharides requires a more detailed knowledge. In this study we aimed i) to develop a standardised multivalent PnPS-IgM and IgA-ELISA, and ii) to compare the sensitivity of the multivalent to the serotype specific antibody response, and iii) to determine the kinetics of the anti-PnPS IgM and IgA antibodies in healthy subjects.
We immunised n = 20 healthy adults with a 23-valent PnPS vaccine (Pneumovax®). The kinetics of the 23-valent antibody response was assessed for 1 year with newly developed ELISAs for IgM and IgA isotypes, along with serotype specific responses.
The IgA and IgM antibody response peaked at 2 and 3 weeks, respectively. IgM antibody levels remained at a plateau (above 80 % of peak response) for 3 months. After one year, specific antibody levels were still at about 30 % of the peak response. The 23-valent antibody response yielded significantly higher responder rates than assessment of single serotypes.
Testing the IgM and IgA immune response to polysaccharide vaccination with a multivalent PnPS ELISA may be a feasible tool for assessment of the immune function in patient groups who receive IgG replacement therapy.
- Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev. 2011;12(2):111–8. CrossRef
- Tessmer A, Welte T, Schmidt-Ott R, Eberle S, Barten G, Suttorp N, et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J. 2011;38(1):147–53. CrossRef
- Tangye SG, Good KL. Human IgM + CD27+ B cells: memory B cells or “memory” B cells? J Immunol. 2007;179(1):13–9.
- Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol. 2007;124(3):294–303. CrossRef
- Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol. 1996;98(1):205–15. CrossRef
- Sorensen RU, Leiva LE, Javier III FC, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998;102(2):215–21. CrossRef
- Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007;25(30):5467–84. CrossRef
- Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol. 2005;115(2):412–7. CrossRef
- Lortan JE, Kaniuk AS, Monteil MA. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin Exp Immunol. 1993;91(1):54–7. CrossRef
- Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis. 1990;161(4):736–40. CrossRef
- Goldblatt D, Nahm M. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). 2010; Available at: http://www.vaccine.uab.edu/ELISAProtocol(89SF).pdf. Accessed 05/2012.
- van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J. 2005;25(3):482–9. CrossRef
- Murphy KM, Travers P, Walport M, Janeway CA, Seidler L, Ehrenstein M. Janeway Immunology. 6th ed.; 2007.
- O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597–606. CrossRef
- Alachkar H, Taubenheim N, Haeney MR, Durandy A, Arkwright PD. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol. 2006;120(3):310–8. CrossRef
- Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol. 2009;157 Suppl 1:12–6. CrossRef
- Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects
Journal of Clinical Immunology
Volume 33, Issue 1 , pp 288-296
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Pneumococcal polysaccharides
- 23 PCP ELISA
- PCP antibody kinetics
- Industry Sectors
- Author Affiliations
- 1. Clinic for Immunodeficiencies, Paediatric Pulmonology, Allergy and Neonatology, Hanover Medical School, Carl-Neuberg Str. 1, 30625, Hanover, Germany
- 2. The Binding Site Group Ltd., Birmingham, UK
- 3. Clinical Immunology, Sapienza University of Rome, Rome, Italy
- 4. Department of Clinical Immunology and Allergy, Medical Faculty of Masaryk University, St. Anne’s University Hospital, Brno, Czech Republic
- 5. The Binding Site Deutschland GmbH, Schwetzingen, Germany
- 6. Clinical Immunology and Rheumatology, Hanover Medical School, Hanover, Germany